MimiVax
Major Drugs - Buffalo, NY, US
MimiVax Employees
MimiVax Senior Management
MimiVax Details
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival ratesMimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)
MimiVax Technologies
Captcha
reCAPTCHA
CMS
WordPress.org
Tag Management
Google Tag Manager
Fonts
Google Font API
Hosting
GoDaddy Hosting
Other
Mobile Friendly